(S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction
Fig 4
(S)-(-)-blebbistatin O-benzoate upregulates expression of skin barrier function genes in keratinocytes.
(A) Viability of keratinocytes exposed to (S)-(-)-blebbistatin O-benzoate for 48 h. (B) Morphology of keratinocytes differentiation incubated Ca2+, (S)-(-)-blebbistatin O-benzoate, or normal medium for 48 h. (C) Gene expression of epidermal barrier-related molecules FLG, loricrin (LOR), involucrin (INV), and (D) ceramide production pathway-related genes SMPD1, SPTLC2, and GBA in keratinocytes incubated with (S)-(-)-blebbistatin O-benzoate for 72 h. Data represent mean ± SE (n = 3/group) and are average values of three independent experiments, *p < 0.05 and **p < 0.01 vs. PBS control.